U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart

Fibrobiologics Announces $1.7 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

Press Release: FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Fibrobiologics General Counsel Ruben A. Garcia Reports Acquisition of Common Shares

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

FibroBiologics announces payoff of outstanding debt

Fibrobiologics Announces Payoff of Outstanding Debt

Fibrobiologics Inc - Pays off All Amounts Outstanding Under Convertible Notes Issued to Ya Ii Pn, Ltd.

FibroBiologics Repays All Outstanding Convertible Debt, Eliminates Further Dilution

BRIEF-Fibrobiologics Announces Closing Of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

FibroBiologics Closes $1.5 Million Registered Direct Share Offering

FibroBiologics Raises $1.5 Million in Private Placement of Unregistered Warrants

Fibrobiologics Announces Closing of $1.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

FibroBiologics Announces Securities Purchase Agreement

FibroBiologics prices 4.48M shares at 33.5c in registered direct offering

FibroBiologics Announces Private Placement of Unregistered Warrants for $1.5 Million

Fibrobiologics Inc - to Issue 4,477,614 Shares of Common Stock at $0.335 Each

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

FibroBiologics Is Maintained at Buy by D. Boral Capital

Fibrobiologics Receives Hrec Approval for Phase 1/2 Clinical Trial for Cywc628 for the Treatment of Refractory Diabetic Foot Ulcers